Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,932.00
Bid: 1,942.00
Ask: 1,944.00
Change: -41.00 (-2.08%)
Spread: 2.00 (0.103%)
Open: 1,967.00
High: 1,973.00
Low: 1,926.00
Prev. Close: 1,973.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broker tips: Johnston Press, Direct Line, Hikma Pharmaceuticals

Thu, 04th Aug 2016 11:01

(ShareCast News) - Johnston Press shares plunged on Thursday as Numis placed its rating and target price 'under review' after the company swung to a first half loss.For the 26 weeks to 2 July, the company posted a statutory pre-tax loss of £183.7m versus a £2.2m profit the year before, as it booked a £183.6m non-cash impairment reflecting a change of assumptions on its publishing titles and print assets.Advertising revenues were down 17.9% in the first quarter but improved marginally, with a 15% drop in the second quarter despite the impact of the run-up to and uncertainty following the UK's vote to leave the European Union in June.Chief executive Ashley Highfield said the market continues to be challenging and uncertainty surrounding the outcome of the Brexit negotiations has caused further softness in some segments of the advertising market, in June and July.Numis said the half year results came in below its estimates at every level."Our key issue at Johnston remains debt which has risen to £209m (from £179.4m) representing almost 4x our annualised EBITDA."This material debt pile, relative to cashflows, in combination with the declining and uncertain trading environment place a significant question mark on the equity value in the business."Numis said it expects to cut estimates "reasonably sharply" in both fiscal years 2016 and 2017. Direct Line Insurance Group's rating has been downgraded to 'hold' from 'buy' by Berenberg as the broker said "questions remain about earnings sustainability"."We believe there is some risk regarding the sustainability of Direct Line's earnings," Berenberg said in a note on Wednesday."High reserve releases, lower than forecast cost savings and a shrinking direct market all cast doubt on future earnings."Berenberg said older accident years have been incredibly profitable for Direct Line but these years are now contributing increasingly less releases.The broker said it does not expect to see the same developments in more recent accident years. Berenberg believes it will be difficult for management to offset falling reserve releases with the current accident year and operating improvements."As reserve releases decline, we expect earnings to be flat at best, thus we believe it will be challenging to grow the dividend from here," the broker said.Berenberg reiterated a target price of 406p.Direct Line on Tuesday posted its half year report for the six months to 30 June on Tuesday. Operating profit fell 5% to £316.9m, hurt by lower investment gains and the new Flood Re levy, but the group beat its own consensus estimates of £263m. Analysts at Citi downgraded their recommendation on shares of Hikma Pharmaceuticals in the wake of the company´s trading update which was issued after the close of trading in London on 3 August.Hikma flagged new drug approvals were arriving more slowly than expected and the phasing of litigation costs at US generics.On the basis of the above, the broker´s analysts lowered their recommendation on the shares from 'buy' to 'neutral' and set a target price of 2,600p.They also lowered estimates for the drugmaker´s core 2016 earnings before interest and taxes and earnings per share by 9.0% to $367m and $1.08, respectively - below the equivalent figures of $420m and $1.22 expected by the consensus.EPS estimates from 2017 onwards were cut by between 2% and 5% from 2017 onwards, with rates in foreign exchange markets expected to be an "incremental headwind".What was Citi´s view? "Developments at US Generics at best can be described as a 'short term hiccup'. At worse, sentiment concerns around the revenue/margin potential from the Roxane pipeline will increase, which is not helped by the lack of clarity on the pipeline given commercial sensitivities until 2017."If one were to cut his Roxane pipeline estimates by half, that would lead to EPS downgrades of between -15.0% and -20.0%, Citi said.Citi estimated the company´s net present value (NPV) at 2,900p, with a weighted average cost of capital of 8.0%, a terminal growth value (the rate at which free cash flows are expected to grow for eternity) of 2.0% and cable´s exchange rate at 1.32.
More News
20 Apr 2022 09:16

IN BRIEF: Hikma gets preliminary US approval for Custopharm acquisition

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Receives preliminary approval from the US Federal Trade Commission for its planned acquisition of Custopharm Inc. Back in September, Hikma agreed to buy the California, US-based generic injectable products company for a total of up to USD425 million.

Read more
20 Apr 2022 07:39

Hikma gets preliminary approval from US FTC for Custopharm deal

(Sharecast News) - Hikma Pharmaceuticals has received preliminary approval from the US Federal Trade Commission for the acquisition of sterile injectables company Custopharm Inc from Water Street Healthcare for up to $425m.

Read more
12 Apr 2022 10:11

LONDON BROKER RATINGS: JPMorgan lowers Rolls-Royce; UBS likes Ryanair

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
10 Mar 2022 16:10

UK dividends calendar - next 7 days

Friday 11 March  
Avon Protection PLCdividend payment date
Civitas Social Housing PLCdividend payment date
Impact Healthcare REIT PLCdividend payment date
Virgin Money UK PLCdividend payment date
Monday 14 March  
Tritax EuroBox PLCdividend payment date
Tuesday 15 March 
Hipgnosis Songs Fund Ltddividend payment date
Invesco Perpetual UK Smaller Cos Investment Trust PLCdividend payment date
Merchants Trust PLCdividend payment date
Wednesday 16 March  
no events scheduled 
Thursday 17 March  
Anglo American PLCex-dividend date
Anglo American PLCspecial ex-dividend date
Bellevue Healthcare Trust PLCex-dividend date
Blackrock Income & Growth Investment Trust PLCdividend payment date
BlacKRock World Mining Trust PLCex-dividend date
Brooks Macdonald Group PLCex-dividend date
Crest Nicholson Holdings PLCex-dividend date
Dunelm Group PLCex-dividend date
FW Thorpe PLCex-dividend date
FW Thorpe PLCspecial ex-dividend date
Gore Street Energy Storage Fund PLCex-dividend date
HgCapital Trust PLCex-dividend date
Hikma Pharmaceuticals PLCex-dividend date
Ideagen PLCdividend payment date
JPMorgan Mid Cap Investment Trust PLCex-dividend date
Knights Group Holdings PLCdividend payment date
M&G PLCex-dividend date
Murray Income Trust PLCdividend payment date
NatWest Group PLCex-dividend date
RM PLCex-dividend date
Segro PLCex-dividend date
Spirent Communications PLCex-dividend date
Standard Life Private Equity Trust PLCex-dividend date
Treatt PLCdividend payment date
Trifast PLCex-dividend date
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
3 Mar 2022 10:02

LONDON BROKER RATINGS: Downgrades for Hikma Pharma and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
3 Mar 2022 08:28

LONDON BRIEFING: LSEG says Refinitiv savings bigger, ahead of schedule

(Alliance News) - London Stock Exchange Group on Thursday said 2021 was a successful year following the acquisition of Refinitiv, leaving the stock exchange operator well positioned as a financial market infrastructure and data business.

Read more
2 Mar 2022 09:52

LONDON BROKER RATINGS: Downgrades for AB Foods, BT and Royal Mail

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
25 Feb 2022 09:40

IN BRIEF: Hikma Pharmaceuticals launches first phase of share buyback

Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase will begin on Friday and end by June 25. Hikma had announced the buyback programme with its annual results, saying it reflected its strong cash generation, balance sheet strength, and confidence in future growth prospects. Hikma also had declared a final dividend of 36 cents, a 5.9% boost from a shareholder payout of 34 cents the year before. Its full-year dividend amounted to 54 US cents, up 8.0% from 50 cents.

Read more
25 Feb 2022 08:22

LONDON BRIEFING: IAG expects to fly 85% of pre-virus capacity in 2022

(Alliance News) - International Consolidated Airlines Group on Friday posted a narrowed loss for 2021, saying that after the setback caused by Omicron at the end of the year, bookings have rebounded strongly and it expects to fly 85% of its 2019 capacity in 2022.

Read more
24 Feb 2022 10:31

TOP NEWS: Hikma Pharmaceutical records revenue growth and lifts payout

(Alliance News) - Hikma Pharmaceutical PLC on Thursday reported full-year revenue growth on a "strong" performance by its three business segments and lifted its shareholder payout.

Read more
24 Feb 2022 07:58

Hikma Pharmaceutical delivers year of 'solid growth' and 'strategic momentum'

(Sharecast News) - Drugmaker Hikma Pharmaceutical said on Thursday that it had delivered another successful year of "solid growth and continued strategic momentum", with both revenue and operating profits improving year-on-year.

Read more
24 Feb 2022 07:50

LONDON MARKET PRE-OPEN: Share buybacks for Lloyds Banking and Hikma

(Alliance News) - Stock prices in London are seen opening sharply lower, with the FTSE 100 called down almost 200 points, amid fear of a full-scale war in eastern Europe after Russia announced the beginning of a military operation in Ukraine.

Read more
17 Feb 2022 16:08

UK earnings, trading statements calendar - next 7 days

Friday 18 February  
NatWest Group PLCFull Year Results
Pod Point Group Holdings PLCFull Year Results
Segro PLCFull Year Results
TBC Bank Group PLCFull Year Results
Monday 21 February 
Bank of Cyprus Holdings PLCFull Year Results
Dechra Pharmaceuticals PLCHalf Year Results
Finsbury Food Group PLCHalf Year Results
Sylvania Platinum LtdHalf Year Results
Tristel PLCTrading Statement
Wilmington PLCHalf Year Results
Tuesday 22 February 
Antofagasta PLCFull Year Results
Bank of Georgia Group PLCFull Year Results
Benchmark Holdings PLCQ1 Results
Blancco Technology Group PLCHalf Year Results
Bluefield Solar Income Fund LtdHalf Year Results
Coca-Cola HBC AGFull Year Results
Hargreaves Lansdown PLCHalf Year Results
HSBC Holdings PLCFull Year Results (at 0400 GMT)
InterContinental Hotels Group PLCFull Year Results
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Smith & Nephew PLCFull Year Results
Springfield Properties PLCHalf Year Results
Synectics PLCFull Year Results
Transense Technologies PLCHalf Year Results
Wednesday 23 February 
Aston Martin Lagonda Global Holdings PLCFull Year Results
Barclays PLCFull Year Results
Capital & Counties Properties PLCFull Year Results
CAP-XX LtdHalf Year Results
Georgia Capital PLCFull Year Results
International Personal Finance PLCFull Year Results
Irish Residential Properties REIT PLCFull Year Results
Metro Bank PLCFull Year Results
Hochschild Mining PLCFull Year Results
Photo-Me International PLCFull Year Results
Rio Tinto PLCFull Year Results
Seraphim Space Investment Trust PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCFull Year Results
Thursday 24 February 
Anglo American PLCFull Year Results
BAE Systems PLCFull Year Results
Centrica PLCFull Year Results
Conduit Holdings LtdFull Year Results
Derwent London PLCFull Year Results
Drax Group PLCFull Year Results
Genus PLCHalf Year Results
Hays PLCHalf Year Results
Hikma Pharmaceuticals PLCFull Year Results
Howden Joinery Group PLCFull Year Results
Inchcape PLCFull Year Results
Lloyds Banking Group PLCFull Year Results
Macfarlane Group PLCFull Year Results
Morgan Sindall Group PLCFull Year Results
Rathbone Group PLCFull Year Results
Ricardo PLCHalf Year Results
Rolls-Royce Holdings PLCFull Year Results
Serco Group PLCFull Year Results
Spectris PLCFull Year Results
St James's Place PLCFull Year Results
Tremor International LtdFull Year Results
WPP PLCFull Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
9 Feb 2022 09:48

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

LONDON BROKER RATINGS: Barclays downgrades Chemring and boohoo

Read more
3 Feb 2022 09:12

Hikma completes acquisition of Teligent's Canadian assets

Hikma completes acquisition of Teligent's Canadian assets

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.